|Chlamydia trachomatis serovars L1-L3
|How far to trace back
|Usual testing method
|Nucleic acid amplification testing of swab from anus, genital ulcer or bubo aspirate, confirmed by genotyping
|Proctitis is common among GBMSM with rectal LGV. Genital ulceration and inguinal buboes are seen less commonly.
|Likelihood of transmission per act of condomless intercourse
|Likelihood of long-term sexual partner being infected
|Protective effect of condoms
|Transmission by oral sex
|Duration of potential infectivity
|Uncertain, probably weeks to months
|Chronic proctocolitis, inguinal abscess
|Direct benefit of detection and treatment of contact
|Usual management of contacts
Chlamydia testing: urine, pharyngeal and anal swab for GBMSM and at risk trans feminine people;
Cervical swab for people with a cervix;
Test any genital ulcer or bubo aspirate.
Alert the laboratory to the possibility of LGV genotyping is performed on chlamydia-positive specimens to identify LGV.
Follow up BBV testing also (HIV, syphilis and hepatitis serology)
|Contact tracing priority
|High as the number of LGV cases reported in Australasia has been limited
|Notifiable by laboratories in some Australian states and territories; not notifiable in New Zealand
Page last updated September 2022